Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Grifols S.A. Leading producer of plasma-derived medicines for patients with rare and chronic diseases.	Spain	GRF
Grifols SA Develops plasma-derived medicines and transfusion solutions for rare and chronic conditions.	United States of America	GRFS
Grindeks Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.	Latvia	GRD1R
GSK plc Develops specialty medicines and vaccines to prevent and treat a range of global diseases.	United States of America	GSK
GT Biopharma, Inc. Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.	United States of America	GTBP
Guardant Health, Inc. Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.	United States of America	GH
Guard Therapeutics International AB Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.	Sweden	GUARD
GW Vitek CO.,LTD. Develops research antibodies and distributes scientific instruments for life science researchers.	South Korea	036180
GYRE THERAPEUTICS, INC. Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.	United States of America	GYRE
Haleon plc A consumer healthcare leader offering trusted OTC brands for everyday health and wellness.	United States of America	HLN